Everolimus
Olema Oncology, Inc. • Cancer
Résumé
Everolimus est développé par Olema Oncology, Inc.. Le traitement est actuellement en Phase 1. Il est associé à Cancer. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 1
Objectif scientifique de l’étude
classification automatique vérifiableIl mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT05508906, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassification scientifique multi-axes
ne pas confondre statut et résultatUn essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifAucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
35 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2013-04-29 | Début de l’étudeNCT01713946 | Registre d’essai clinique |
| 2014-03-01 | Début de l’étudeNCT02061397 | Registre d’essai clinique |
| 2017-10-25 | Fin de l’étude prévue / enregistréeNCT01713946 | Registre d’essai clinique |
| 2018-05-24 | Début de l’étudeNCT03198949 | Registre d’essai clinique |
| 2019-12-13 | Fin de l’étude prévue / enregistréeNCT02061397 | Registre d’essai clinique |
| 2020-09-11 | Fin de l’étude prévue / enregistréeNCT03198949 | Registre d’essai clinique |
| 2022-08-31 | Début de l’étudeNCT05508906 | Registre d’essai clinique |
| 2023-04-07 | Début de l’étudeNCT05709626 | Registre d’essai clinique |
| 2024-11-16 | Début de l’étudeNCT06718179 | Registre d’essai clinique |
| 2025-05-30 | Fin de l’étude prévue / enregistréeNCT06718179 | Registre d’essai clinique |
| 2026-04-27 | Fin de l’étude prévue / enregistréeNCT05709626 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT01713946 | Registre d’essai clinique |
| 2026-07-08 | PublicationVery late stent thrombosis associated with stent malapposition and uncovered struts after contrast-enhanced CT in a patient receiving long-term steroid therapy due to Kounis syndrome: a case report. | European heart journal. Case reports |
| 2026-07-13 | Dernière mise à jour du registreNCT01713946 | Registre d’essai clinique |
| 2026-07-14 | Création de l’enregistrementNCT02061397 | Registre d’essai clinique |
| 2026-07-14 | PublicationSustained Disease Control of High-Risk Metastatic Renal Epithelioid Angiomyolipoma through Multimodal Treatment Including Repeated Thoracic Resection and Systemic Therapy: A Case Report. | Case reports in oncology |
| 2026-07-23 | PublicationRegulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |
| 2026-07-23 | PublicationDrug repurposing as a promising therapeutic strategy against renal cell carcinoma. | Cancer chemotherapy and pharmacology |
| 2026-08-05 | Création de l’enregistrementNCT03198949 | Registre d’essai clinique |
| 2026-08-08 | PublicationAdvances in Endovascular Therapy for Infrainguinal Peripheral Arterial Disease: Devices and Outcomes. | The International journal of angiology : official publication of the International College of Angiology, Inc |
| 2026-08-08 | PublicationEverolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial. | Journal of medical genetics |
| 2026-08-08 | PublicationDementia as a rare neurological adverse event of Nivolumab in a patient with metastatic renal cell carcinoma. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |
| 2026-08-08 | PublicationAnalysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov. | Current medicinal chemistry |
| 2026-08-08 | PublicationIntravenous Everolimus Formulation (Sapu003) for Clinical Trials. | International journal of molecular sciences |
| 2026-08-16 | PublicationDrug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models. | Biomaterials advances |
| 2026-08-16 | PublicationComparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials. | Annals of medicine |
| 2026-08-16 | PublicationCXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. | Cell death discovery |
| 2026-08-16 | PublicationLessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. | Journal of immunotherapy and precision oncology |
| 2026-08-16 | PublicationmTOR signaling is required for phagocyte free radical production, GLUT1 expression, and control of infection. | mBio |
| 2026-08-16 | PublicationImlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. | Cancer research |
| 2026-10-25 | Création de l’enregistrementNCT06718179 | Registre d’essai clinique |
| 2026-11-09 | Création de l’enregistrementNCT05709626 | Registre d’essai clinique |
| 2026-11-17 | Dernière mise à jour des donnéesEverolimus | Biomedical Watch |
| 2026-11-22 | Création de l’enregistrementNCT05508906 | Registre d’essai clinique |
| 2028-01-31 | Fin de l’étude prévue / enregistréeNCT05508906 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
6 essai(s)
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | ACTIVE_NOT_RECRUITING | United States, Australia | Olema Oncology, Inc. |
| NCT05709626 | PREMIUM — PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction | Phase 4 | COMPLETED | Japan | Kindai University |
| NCT06718179 | SORT OUT DAPT — Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents | Phase 4 | TERMINATED | Denmark | Odense University Hospital |
| NCT03198949 | A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | Phase 2 | COMPLETED | South Korea | Yonsei University |
| NCT02061397 | Safety of Simvastatin in LAM and TSC | Phase 1 | COMPLETED | United States | University of Pennsylvania |
| NCT01713946 | A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | Phase 3 | COMPLETED | United States, Argentina, Australia, Belgium, Canada, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, South Korea, … | Novartis Pharmaceuticals |
Publications liées
15 publication(s)Publications liées
15 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models. Voir source | 42385450 | 10.1016/j.bioadv.2026.215029 | Biomaterials advances | |
| Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials. Voir source | 41631490 | 10.1080/07853890.2026.2623329 | Annals of medicine | |
| CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. Voir source | 41896541 | 10.1038/s41420-026-03026-w | Cell death discovery | |
| Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. Voir source | 41868199 | 10.36401/JIPO-25-34 | Journal of immunotherapy and precision oncology | |
| mTOR signaling is required for phagocyte free radical production, GLUT1 expression, and control of infection. Voir source | 38767353 | 10.1128/mbio.00862-24 | mBio | |
| Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. Voir source | 39652577 | 10.1158/0008-5472.CAN-24-2608 | Cancer research | |
| Advances in Endovascular Therapy for Infrainguinal Peripheral Arterial Disease: Devices and Outcomes. Voir source | 42559651 | 10.1055/a-2798-9625 | The International journal of angiology : official publication of the International College of Angiology, Inc | |
| Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial. Voir source | 42562625 | 10.1136/jmg-2026-111529 | Journal of medical genetics | |
| Dementia as a rare neurological adverse event of Nivolumab in a patient with metastatic renal cell carcinoma. Voir source | 42530546 | 10.1177/10781552261474047 | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | |
| Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov. Voir source | 40103456 | 10.2174/0109298673345472250301052255 | Current medicinal chemistry | |
| Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. Voir source | 42450048 | 10.3390/ijms27135775 | International journal of molecular sciences | |
| Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial. Voir source | 42486389 | 10.1016/j.ajt.2026.07.016 | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | |
| Drug repurposing as a promising therapeutic strategy against renal cell carcinoma. Voir source | 42479152 | 10.1007/s00280-026-04923-8 | Cancer chemotherapy and pharmacology | |
| Sustained Disease Control of High-Risk Metastatic Renal Epithelioid Angiomyolipoma through Multimodal Treatment Including Repeated Thoracic Resection and Systemic Therapy: A Case Report. Voir source | 42445892 | 10.1159/000552721 | Case reports in oncology | |
| Very late stent thrombosis associated with stent malapposition and uncovered struts after contrast-enhanced CT in a patient receiving long-term steroid therapy due to Kounis syndrome: a case report. Voir source | 41972237 | 10.1093/ehjcr/ytag199 | European heart journal. Case reports |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-11-17
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.